ClinVar Miner

Submissions for variant NM_001130987.2(DYSF):c.1449G>A (p.Met483Ile) (rs146064054)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000726239 SCV000343118 uncertain significance not provided 2018-08-30 criteria provided, single submitter clinical testing
GeneDx RCV000726239 SCV000536482 uncertain significance not provided 2017-01-23 criteria provided, single submitter clinical testing The c.1353 G>A variant in the DYSF gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The c.1353 G>A variant was not observed at any significant frequency in approximately 6,500 individuals of European and African American ancestry by the NHLBI Exome Sequencing Project. In-silico splice prediction models predict that c.1353 G>A may damage or destroy the splice donor site in exon 14. However, in the absence of RNA/functional studies, the actual effect of c.1353 G>A change in this individual is unknown. If c.1353 G>A does not alter splicing, it will result in the M451I missense change. The M451I variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is conserved in mammals. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret c.1353 G>A as a variant of uncertain significance.
Claritas Genomics RCV000449523 SCV000537828 uncertain significance Peripheral neuropathy 2016-08-22 criteria provided, single submitter clinical testing
Invitae RCV000648013 SCV000769823 uncertain significance Qualitative or quantitative defects of dysferlin 2019-08-20 criteria provided, single submitter clinical testing This sequence change replaces methionine with isoleucine at codon 451 of the DYSF protein (p.Met451Ile). The methionine residue is moderately conserved and there is a small physicochemical difference between methionine and isoleucine. This variant also falls at the last nucleotide of exon 14 of the DYSF coding sequence, which is part of the consensus splice site for this exon. This variant is present in population databases (rs146064054, ExAC 0.06%). This variant has not been reported in the literature in individuals with DYSF-related disease. ClinVar contains an entry for this variant (Variation ID: 288879). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.